How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,318 results for

fluoroquinolones

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Fluoroquinolones: use should be restricted due to severe adverse effects

Fluoroquinolones: use should be restricted due to severe adverse effects Prescrire IN ENGLISH - Spotlight '' Fluoroquinolones: use should be restricted due to severe adverse effects'', 1 September 2019 {1} {1} {1} | | > > > Fluoroquinolones: use should be restricted due to severe adverse effects Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight (...) Fluoroquinolones: use should be restricted due to severe adverse effects Given the many and sometimes severe adverse effects of fluoroquinolone antibiotics, they should only be used for limited purposes. Fluoroquinolones are a group of antibiotics that are effective on many bacteria. But their adverse effects are many and sometimes severe, which has led to the gradual limitation of their use. The European Pharmacovigilance Committee (PRAC) reassessed all adverse reactions to fluoroquinolones in 2018

2019 Prescrire

2. Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness,

Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness, Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness, | CADTH.ca Find the information you need Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness, Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness, Last updated: May 6, 2019 Project Number (...) : RC1093-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of fluoroquinolones for the treatment of respiratory tract infections? What is the cost-effectiveness of fluoroquinolones for the treatment of respiratory tract infections? What are the evidence-based guidelines for the use of fluoroquinolones for the treatment of respiratory tract infections? Key Message Overall, 15 publications met the eligibility

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones (...) for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: May 31, 2019 Project Number: RC1123-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of fluoroquinolones for the treatment of ‘other’ respiratory tract infections? What is the cost-effectiveness of fluoroquinolones for the treatment of ‘other’ respiratory tract infections

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Fluoroquinolones for the Treatment of Otitis Media: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Fluoroquinolones for the Treatment of Otitis Media: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Otitis Media: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Fluoroquinolones for the Treatment of Otitis Media: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Otitis Media: A Review of Clinical Effectiveness (...) , Cost-Effectiveness, and Guidelines Last updated: April 24, 2019 Project Number: RC1095-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of fluoroquinolones for the treatment of otitis media in patients unable to take beta-lactams antibiotics? What is the cost-effectiveness of fluoroquinolones for the treatment of otitis media in patients unable to take beta-lactams antibiotics? What are the evidence

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

5. Fluoroquinolones for the Treatment of Intra-Abdominal Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Fluoroquinolones for the Treatment of Intra-Abdominal Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Intra-Abdominal Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Fluoroquinolones for the Treatment of Intra-Abdominal Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Intra (...) -Abdominal Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: April 25, 2019 Project Number: RC1094-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of fluoroquinolones for the treatment of intra-abdominal infections? What is the cost-effectiveness of fluoroquinolones for the treatment of intra-abdominal infections? What are the evidence-based guidelines

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Urinary Tract (...) Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: April 26, 2019 Project Number: RC1101-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of fluoroquinolones for the treatment of urinary tract infections? What is the cost-effectiveness of fluoroquinolones for the treatment of urinary tract infections? What are the evidence-based guidelines regarding the use

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects

Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports (...) of disabling and potentially long-lasting or irreversible side effects Disabling, long-lasting or potentially irreversible adverse reactions affecting musculoskeletal and nervous systems have been reported very rarely with fluoroquinolone antibiotics. Fluoroquinolone treatment should be discontinued at the first signs of a serious adverse reaction, including tendon pain or inflammation. Published 21 March 2019 From: Therapeutic area: , , , , , , , , , , , , , Contents Advice for healthcare professionals

2019 MHRA Drug Safety Update

9. Inpatient Fluoroquinolone Stewardship Improves the Quantity and Quality of Fluoroquinolone-prescribing at Hospital Discharge: A Retrospective Analysis among 122 Veterans Health Administration Hospitals. (PubMed)

Inpatient Fluoroquinolone Stewardship Improves the Quantity and Quality of Fluoroquinolone-prescribing at Hospital Discharge: A Retrospective Analysis among 122 Veterans Health Administration Hospitals. Despite increasing awareness of harms, fluoroquinolones are still frequently prescribed to inpatients and at hospital discharge. Our goal was to describe fluoroquinolone-prescribing at hospital discharge across the Veterans Health Administration (VHA) and to contrast fluoroquinolone-prescribing (...) volume and appropriateness across 3 antimicrobial stewardship strategy-types.We analyzed a retrospective cohort of patients hospitalized at 122 VHA acute-care hospitals during 2014-2016. Data from a mandatory VHA survey were used to identify 9 hospitals that self-reported one of 3 strategies for optimizing fluoroquinolone-prescribing: prospective audit-and-feedback (PAF), restrictive policies (RP), and no strategy. Manual chart reviews to assess fluoroquinolone appropriateness at hospital discharge

2019 Clinical Infectious Diseases

10. Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice

Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice | CADTH.ca Find the information you need Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice Last updated: May 1, 2017 Project Number: HT0018-000 - CP0020-000 Product Line: Technology Review Result type: Report The study investigated current practices and implementation (...) issues for antibiotic therapies, particularly fluoroquinolones, for specific indications. The study was conducted from the perspective of family physicians, nurse practitioners, and pharmacists. Indications included: uncomplicated cystitis, uncomplicated pyelonephritis, acute bacterial exacerbation of chronic bronchitis in chronic obstructive pulmonary disease (COPD), and acute bacterial sinusitis. The research findings are based on the results of qualitative research in the form of surveys

2017 CADTH - Technology Review

11. High fluoroquinolone MIC is associated with fluoroquinolone treatment failure in urinary tract infections caused by fluoroquinolone susceptible Escherichia coli (Full text)

High fluoroquinolone MIC is associated with fluoroquinolone treatment failure in urinary tract infections caused by fluoroquinolone susceptible Escherichia coli Suboptimal clinical response to fluoroquinolone (FQ) therapy has been clearly documented in patients with Salmonella typhi infection with reduced FQ susceptibility. However, the clinical impact of reduced FQ susceptibility on other infections including E. coli urinary tract infections (UTIs) has never been evaluated.We conducted (...) a retrospective cohort study of female patients with fluoroquinolone susceptible E. coli (FQSEC) UTIs who received FQ therapy at outpatient services within University of Pennsylvania Health System, Philadelphia. Exposed patients were those with high MIC-FQSEC UTIs (the levofloxacin MIC > 0.12 but ≤ 2 mg/L) while unexposed patients were those with low MIC-FQSEC UTIs (the levofloxacin MIC ≤ 0.12 mg/L). The primary treatment outcome was treatment failure within 10 weeks after initiation of FQ therapy.From May

2017 Annals of Clinical Microbiology and Antimicrobials PubMed

12. Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice

Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice | CADTH.ca CADTH Document Viewer Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice Table of Contents Search this document Fluoroquinolone Prescribing and Use in Canadian Primary Care Practice May 2017 1. Introduction CADTH undertook a study into antibiotic prescribing and use in Canadian primary care practice, with a particular emphasis (...) on fluoroquinolone use. The study investigated current practices and implementation issues for antibiotic therapies from the perspective of family physicians (FPs), nurse practitioners (NPs), and pharmacists. The research findings are based on the results of qualitative research in the form of surveys of primary care practitioners, as well as on a targeted review of the literature on fluoroquinolones use in Canada. CADTH sought to understand and explain experiences and decision-making processes around outpatient

2017 CADTH - Plasma Products

13. Do fluoroquinolones increase the incidence of adult tendinopathy?

Do fluoroquinolones increase the incidence of adult tendinopathy? BestBets: Do fluoroquinolones increase the incidence of adult tendinopathy? Do fluoroquinolones increase the incidence of adult tendinopathy? Report By: Janos P Baombe - Consultant in Emergency Medicine Search checked by Rebecca Ford - Royal Oldham Hospital, Oldham, Lancashire, UK Institution: Manchester Royal Infirmary, Manchester, UK Date Submitted: 10th February 2017 Last Modified: 10th February 2017 Status: Green (complete (...) ) Three Part Question In [adult patients receiving fluoroquinolone antibiotics] is there [an increased risk] of [developing tendinopathy]? Clinical Scenario You are reviewing urine culture and sensitivity results in your ED. You come across a result growing a germ that is sensitive to ciprofloxacin only. You contact your patient to come and collect a prescription later in the day. Your colleague who has been listening to your phone conversation warns you of the increased risk of tendinopathy

2017 BestBETS

14. Improvement of gram-negative susceptibility to fluoroquinolones after implementation of a pre-authorization policy for fluoroquinolone use: A decade-long experience. (PubMed)

Improvement of gram-negative susceptibility to fluoroquinolones after implementation of a pre-authorization policy for fluoroquinolone use: A decade-long experience. Due to concerns over increasing fluoroquinolone (FQ) resistance among gram-negative organisms, our stewardship program implemented a preauthorization use policy. The goal of this study was to assess the relationship between hospital FQ use and antibiotic resistance.Retrospective cohort.Large academic medical center.We performed (...) . aeruginosa, Acinetobacter spp., and E. cloacae. Our FQ restriction policy improved FQ use from 173 days of therapy (DOT) per 1,000 patient days to <60 DOT per 1,000 patient days. Fluoroquinolone susceptibility increased for Acinetobacter spp. (rate ratio [RR], 1.038; 95% confidence interval [CI], 1.005-1.072), E. cloacae (RR, 1.028; 95% CI, 1.013-1.044), and P. aeruginosa (RR, 1.013; 95% CI, 1.006-1.020). No significant change in susceptibility was detected for K. pneumoniae (RR, 1.002; 95% CI, 0.996

2018 Infection control and hospital epidemiology

15. Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation

Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation Recent studies have linked fluoroquinolones (FQs) to cardiac adverse events, including aortic dissection and aneurysm. To date, whether FQs can increase the risk of aortic or mitral regurgitation has not been studied.This disproportionality analysis and case-control study examined whether FQs increase the risk of aortic and mitral regurgitation.Data from the U.S. Food and Drug Administration's adverse reporting system database

2019 EvidenceUpdates

16. Resolution of fluoroquinolone-resistant Escherichia coli keratitis with a PROSE device for enhanced targeted antibiotic delivery (Full text)

Resolution of fluoroquinolone-resistant Escherichia coli keratitis with a PROSE device for enhanced targeted antibiotic delivery To report the resolution of a fluoroquinolone-resistant Escherichia coli keratitis with use of a prosthetic replacement of the ocular surface ecosystem (PROSE) device for enhanced targeted delivery of moxifloxiacin.A 62-year-old female presented with a 3-day history of pain, photophobia, and declining vision in left eye. The patient had a 2-year history of binocular (...) . Four days later, the corneal surface was epithelialized with only small subepithelial infiltrate remaining. The corneal culture grew an E. coli isolate carrying multiple mutations in the topoisomerase genes. These mutations were correlated with varying levels of resistance to ciprofloxacin (256 μg/mL), levofloxacin (8 μg/mL), and moxifloxacin (16 μg/mL).Although the infecting E. coli strain exhibited resistance to fluoroquinolones, the infection resolved when moxifloxacin was combined with PROSE

2018 American journal of ophthalmology case reports PubMed

17. Fluoroquinolone-related adverse events resulting in health service use and costs: A systematic review. (Full text)

Fluoroquinolone-related adverse events resulting in health service use and costs: A systematic review. Adverse events (AEs) associated with the use of fluoroquinolone antimicrobials include Clostridium difficile associated diarrhea (CDAD), liver injury and seizures. Yet, the economic impact of these AEs is seldom acknowledged. The aim of this review was to identify health service use and subsequent costs associated with ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin and ofloxacin (...) of fluoroquinolones, in particular serious fluoroquinolone-related AEs can have substantial economic implications, in addition to imposing potentially devastating health complications for patients. Further measures are required to prevent and reduce health service use and costs associated with fluoroquinolone-related AEs. Equally, better-quality reporting and additional published data on health service use and costs associated with AEs are needed.

2019 PLoS ONE PubMed

18. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. (Full text)

Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. To investigate whether oral fluoroquinolone use is associated with an increased risk of aortic aneurysm or dissection.Nationwide historical cohort study using linked register data on patient characteristics, filled prescriptions, and cases of aortic aneurysm or dissection.Sweden, July 2006 to December 2013.360 088 treatment episodes of fluoroquinolone use (78%ciprofloxacin) and propensity score matched (...) comparator episodes of amoxicillin use (n=360 088).Cox regression was used to estimate hazard ratios for a first diagnosis of aortic aneurysm or dissection, defined as admission to hospital or emergency department for, or death due to, aortic aneurysm or dissection, within 60 days from start of treatment.Within the 60 day risk period, the rate of aortic aneurysm or dissection was 1.2 cases per 1000 person years among fluoroquinolone users and 0.7 cases per 1000 person years among amoxicillin users

2018 BMJ PubMed

19. The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis

The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis Quinolones were contraindicated during pregnancy because of concerns regarding fetal malformations and carcinogenesis in animals. The literature is conflicting regarding their safety in humans.To conduct a meta-analysis evaluating the risk for fetal malformations and pregnancy complications following exposure to quinolones during pregnancy.We searched Embase, PubMed, Medline, the Cochrane database, clinicaltrials.gov (...) , and Dart Databases. We added articles found through the references of included articles.Relevant English citations using the terms quinolone/s, fluoroquinolone/s, and pregnancy in humans. Exclusion criteria were case reports, reviews, and articles without data regarding the study outcomes.Two authors performed the database search, assessment of eligibility, and abstraction of data from included studies. Disagreement was settled by consensus among all authors. The pooled odds ratios (with 95% CIs) were

2018 EvidenceUpdates

20. Relationship between fluoroquinolones and the risk of aortic diseases: a meta-analysis of observational studies

Relationship between fluoroquinolones and the risk of aortic diseases: a meta-analysis of observational studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>